Autolus Ltd.

autolus.com

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

news image

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More

MedTech

ENTOS AND BIOMARIN ENTER INTO AGREEMENT FOR PRODUCT CANDIDATES INCORPORATING ENTOS' FUSOGENIX DRUG DELIVERY PLATFORM

Entos Pharmaceuticals, Inc., BioMarin | November 16, 2021

news image

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline. Under the agreement, Entos will create specially formulated product candidate...

Read More

Medical

INVIVOSCRIBE ANNOUNCES FDA APPROVAL OF THE LEUKOSTRAT CDX FLT3 MUTATION ASSAY TO SELECT PATIENTS WITH FLT3-ITD POSITIVE AML

PRNewswire | July 27, 2023

news image

Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib). The LeukoStrat CDx FLT3 Mutation Assay identifies FLT3-ITD positive AML patients who may be treated with this newly approved targeted...

Read More

Industrial Impact, Medical

MOLECULAR ASSEMBLIES DELIVERS FIRST ENZYME-SYNTHESIZED OLIGONUCLEOTIDES

Molecular Assemblies, Inc. | March 15, 2023

news image

On March 14, 2023, Molecular Assemblies, Inc., a leading life sciences company, made a significant announcement regarding its enzymatic DNA synthesis technology. The company has successfully shipped the first enzymatically synthesized oligonucleotides to leading researchers in biotechnology, academic, and synthetic biology. The capacity to synthesize lengthy, extremely pure DNA promptly utilizing a proprietary Fully Enzymatic Synthesis (FES) technology solves critical unmet demands in DNA ...

Read More
news image

CORONAVIRUS VACCINES ARE MOVING TOWARDS CLINICAL TRIALS, PROMISES SEVERAL BIOTECH COMPANIES IN THE US

Edex Live | April 09, 2020

Just three months after the outbreak of the coronavirus pandemic, several biotech companies in the United States have ramped up their efforts to fight the disease with accelerated schedules for creating new vaccines and beginning clinical trials for potential treatments. In normal circumstances, vaccine development would take around 10 years. But the pharmaceutical industry is racing to compress this timeline with the support of non-profit organisations, government agencies and regulatory author...

Read More
news image

MedTech

ENTOS AND BIOMARIN ENTER INTO AGREEMENT FOR PRODUCT CANDIDATES INCORPORATING ENTOS' FUSOGENIX DRUG DELIVERY PLATFORM

Entos Pharmaceuticals, Inc., BioMarin | November 16, 2021

Entos Pharmaceuticals, Inc. (Entos), a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, and BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that they have entered into an agreement that will see Entos apply its Fusogenix nucleic acid delivery technology to promising gene therapy candidates in the BioMarin pipeline. Under the agreement, Entos will create specially formulated product candidate...

Read More
news image

Medical

INVIVOSCRIBE ANNOUNCES FDA APPROVAL OF THE LEUKOSTRAT CDX FLT3 MUTATION ASSAY TO SELECT PATIENTS WITH FLT3-ITD POSITIVE AML

PRNewswire | July 27, 2023

Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo's VANFLYTA® (quizartinib). The LeukoStrat CDx FLT3 Mutation Assay identifies FLT3-ITD positive AML patients who may be treated with this newly approved targeted...

Read More
news image

Industrial Impact, Medical

MOLECULAR ASSEMBLIES DELIVERS FIRST ENZYME-SYNTHESIZED OLIGONUCLEOTIDES

Molecular Assemblies, Inc. | March 15, 2023

On March 14, 2023, Molecular Assemblies, Inc., a leading life sciences company, made a significant announcement regarding its enzymatic DNA synthesis technology. The company has successfully shipped the first enzymatically synthesized oligonucleotides to leading researchers in biotechnology, academic, and synthetic biology. The capacity to synthesize lengthy, extremely pure DNA promptly utilizing a proprietary Fully Enzymatic Synthesis (FES) technology solves critical unmet demands in DNA ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us